Webinar - Reata MOXle study
Dear FA Patients, Families and Caregivers,Reata and FARA are pleased to announce a Webinar to update the FA community about the ongoing Phase 2, Part 2 of the MOXle study for RTA 408, and provide a review of Phase 2, Part 1, which has been completed. There will be two Webinars - 1/31/2018 and 2/1/2018. The covered material will be the same, so please plan to join us for one of them. There will be ample time for discussion and questions. Please see additional information below about the Webinar and how to sign up. Thank you and we look forward to having you participate!Sincerely,Katie Schultz, Patient Engagement Director, FARA
Join Reata WebEx. Get updates on the MOXIe Phase 2 StudyPlease join Jennifer Farmer, Executive Director, FARA & Dr. Keith Ward, Chief Development Officer of Reata Pharmaceuticals, for one of two upcoming meetings to discuss the MOXIe clinical trial in more detail.PurposeThe purpose of the WebEx is to discuss and review Part 1 MOXIe data and provide updates to the ongoing Part 2 portion of the study to the patient community, including study participation, eligibility criteria, how to enroll, study status, FAQs, etc. The WebEx meetings will include time at the end for FARA/Reata to answer questions from the participants.Reata is evaluating the safety and effectiveness of an investigational medication, RTA 408 (omaveloxolone), in Friedreich’s ataxia.Meeting Dates and TimesThere will be two meetings. The same information will be presented at both meetings, so pick the time that best fits your schedule. They will be recorded so you can listen to them later if you are unable to attend one live.
- Wednesday, January 31stat 9:00am PST/12:00pm EST
- Thursday, February 1stat 5:00pm PST/8:00pm EST